| Trial ID # | NCT02799095; ARTISTRY-1 |
| Phase | I/II |
| Drug Class | Immunotherapy: Immune Cell Stimulators/IL-2R |
| Drug Name | Nemvaleukin alfa |
| Alternate Drug Names | intermediate-affinity interleukin-2 receptor agonist ALKS 4230, Nemvaleukin, ALKS4230 |
| Drugs in Trial | Nemvaleukin alfa, Pembrolizumab |
| Eligible Participant | Advanced solid tumors |
| Patients Enrolled | 16; median 5 prior therapies (2-6); 60% w/ prior Bev, 20% with prior checkpoint inhibitor therapy |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, DoR, evaluated per RECIST |
| Efficacy | Nem: 36 patients, median 3 prior therapies (1-8), 1 ovarian Nem+Pem: 15 ovarian, median 5 prior therapies (2-6), 14 evaluable |
| Conclusion | Nemvaleukin alfa (ALKS 4230) alone and with pembrolizumab is well tolerated with encouraging clinical benefit |
| Reference | Boni V et al. ARTISTRY-1: Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors. J Clin Oncol (2021) 39 (suppl 15; abstr 2513) Boni V et al. Poster Slide from SGO 2022 presentation; scientific plenary III, abstract 229 Vaishampayan UN et al. Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1. J Clin Oncol 40, 2022 (suppl 16; abstr 2500) Vaishampayan UN et al. Slide from presentation |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.